2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
283
ADVANCED STRATEGIES IN THE MANAGEMENT OF CHRONIC HEART
FAILURE: A MULTIDISCIPLINARY AND EVIDENCE-BASED APPROACH
¹Aliyev Alisher To‘xtamurod o‘g‘li
²Ermatov Farruxjon Baxtiyor o‘g‘li
³Jo‘raboyev Ozodbek Akbar o‘g‘li
¹'²'³Samarkand State Medical University DKTF, Department of Internal Medicine, Cardiology
and Functional Diagnostics! Second-year clinical residents
https://doi.org/10.5281/zenodo.15637019
Research objective
Chronic heart failure (CHF) continues to be one of the most challenging and prevalent
cardiovascular disorders affecting millions of individuals globally. The objective of this research
is to explore and evaluate the most effective, up-to-date multidisciplinary and evidence-based
strategies for managing chronic heart failure, focusing on pharmacologic advancements, device-
based therapy, and integrated care models. The study seeks to assess the role of emerging drugs
like SGLT2 inhibitors, ARNIs, and newer digital health technologies in the clinical outcomes of
CHF patients. By analyzing current literature, clinical guidelines, and real-world evidence, this
research aims to provide a comprehensive synthesis of best practices in CHF treatment that can
be translated into improved patient care, reduced hospitalization rates, and increased survival and
quality of life.
Introduction
: Chronic heart failure is defined as a complex clinical syndrome that results
from any structural or functional impairment of ventricular filling or ejection of blood. The
condition is characterized by symptoms such as fatigue, shortness of breath, and fluid retention,
leading to a reduced capacity to perform daily activities and significantly affecting the quality of
life. The global burden of heart failure is growing due to the aging population, better survival
from acute myocardial infarctions, and increasing prevalence of contributing conditions such as
diabetes mellitus and hypertension. Effective management of CHF not only requires medical
treatment but also a thorough understanding of the pathophysiological mechanisms, early
diagnosis, and the implementation of long-term care strategies.
Materials and Methods
The pathophysiology of heart failure is multifactorial and includes neurohormonal
activation, ventricular remodeling, and endothelial dysfunction. These processes contribute to a
progressive decline in cardiac function and are often accompanied by systemic effects such as
renal dysfunction and pulmonary hypertension. The renin-angiotensin-aldosterone system
(RAAS) and sympathetic nervous system are key players in the progression of CHF. Persistent
activation of these systems leads to vasoconstriction, sodium and water retention, and adverse
myocardial remodeling. Diagnostic evaluation of CHF involves a detailed patient history,
physical examination, and a combination of laboratory and imaging studies. Biomarkers such as
B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) have proven valuable in
the diagnosis, prognosis, and monitoring of therapy in CHF patients. Imaging studies,
particularly transthoracic echocardiography, remain essential tools in assessing left ventricular
function, detecting valvular abnormalities, and estimating pulmonary pressures. Pharmacological
management remains the foundation of CHF therapy.
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
284
Results
: Guideline-directed medical therapy (GDMT) has been established as the
standard of care for patients with heart failure with reduced ejection fraction (HFrEF). This
includes the use of ACE inhibitors or angiotensin receptor blockers (ARBs), beta-blockers,
mineralocorticoid receptor antagonists (MRAs), and more recently, angiotensin receptor-
neprilysin inhibitors (ARNIs). The addition of sodium-glucose cotransporter 2 (SGLT2)
inhibitors has demonstrated a significant reduction in both cardiovascular death and heart failure
hospitalization, irrespective of diabetes status. Non-pharmacologic interventions, including
dietary sodium restriction, fluid management, and structured exercise programs, play a vital role
in symptom control and improving functional capacity. Device-based therapies such as
implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) have
been shown to reduce mortality and improve symptoms in selected patients. In advanced heart
failure, mechanical circulatory support devices like left ventricular assist devices (LVADs) and
heart transplantation remain viable options for eligible candidates. Multidisciplinary care models
involving cardiologists, primary care physicians, nurses, pharmacists, and other healthcare
professionals have been associated with better adherence to treatment, reduced hospitalizations,
and improved outcomes. Telemonitoring and remote patient management are increasingly being
integrated into chronic heart failure programs to enhance early detection of decompensation and
promote timely intervention. A growing div of research is focused on personalized medicine
approaches, leveraging genetic and biomarker data to tailor treatment to individual patient
profiles. Novel therapies under investigation include myosin activators, anti-inflammatory
agents, and regenerative techniques using stem cells and tissue engineering.
Conclusion
: Despite these advances, significant challenges remain in optimizing heart
failure care across different healthcare systems, particularly in low- and middle-income countries
where access to guideline-recommended therapies and devices may be limited. Furthermore,
special consideration must be given to vulnerable populations such as the elderly, women, and
patients with comorbid conditions, who are often underrepresented in clinical trials but constitute
a large portion of the CHF population. In conclusion, chronic heart failure management has
undergone substantial evolution over recent decades, transitioning from a primarily symptomatic
approach to a comprehensive, multifaceted strategy that incorporates pharmacologic, device-
based, lifestyle, and organizational interventions. Continued research, innovation, and equitable
implementation of these strategies are essential for improving patient outcomes and reducing the
global burden of this debilitating condition.
REFERENCE
S
1.
Andryev S. et al. Experience with the use of memantine in the treatment of cognitive
disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
2.
Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood
lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science
and innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
3.
Asanova R. et al. Features of the treatment of patients with mental disorders and
cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 545-
550.
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
285
4.
Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
5.
Bo’Riyev B. et al. Features of clinical and psychopathological examination of young
children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
6.
Borisova Y. et al. Concomitant mental disorders and social functioning of adults with
high-functioning autism/asperger syndrome //Science and innovation. – 2023. – Т. 2. –
№. D11. – С. 36-41.
7.
Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in
non-psychotic depressions in combination with chronic brain ischemia //Science and
Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
8.
Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases
in psychotherapeutic practice //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 898-
903.
9.
Novikov A. et al. Alcohol dependence and manifestation of autoagressive behavior in
patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 413-
419.
10.
Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of
withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. –
2023. – Т. 2. – №. D12. – С. 240-244.
11.
Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of
therapeutic response in patients with paroxysmal schizophrenia //Science and innovation.
– 2023. – Т. 2. – №. D12. – С. 385-391.
12.
Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with
somatized personality development //Science and innovation. – 2023. – Т. 2. – №. D12. –
С. 245-251.
13.
Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
14.
Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological
syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. –
Т. 2. – №. D12. – С. 258-264.
15.
Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia
during prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 392-397.
16.
Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the
formation of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 186-191.
17.
Prostyakova N. et al. Changes in the postpsychotic period after acute polymorphic
disorder //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 356-360.
18.
Zuhridinovna, J. D., & Farrukh, S. (2024). Modern Imaging Techniques for Early
Detection of Retinal Degeneration. American Journal of Bioscience and Clinical
Integrity, 1(11), 22–34.
19.
Prostyakova N. et al. Issues of professional ethics in the treatment and management of
patients with late dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 158-
165.
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
286
20.
Prostyakova N. et al. Sadness and loss reactions as a risk of forming a relationship
together //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 252-257.
21.
Prostyakova N. et al. Strategy for early diagnosis with cardiovascular diseaseisomatized
mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 166-172.
22.
Rotanov A. et al. Comparative effectiveness of treatment of somatoform diseases in
psychotherapeutic practice //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 267-
272.
23.
Rotanov A. et al. Diagnosis of depressive and suicidal spectrum disorders in students of a
secondary special education institution //Science and innovation. – 2023. – Т. 2. – №.
D11. – С. 309-315.
24.
Rotanov A. et al. Elderly epilepsy: neurophysiological aspects of non-psychotic mental
disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 192-197.
25.
Rotanov A. et al. Social, socio-cultural and behavioral risk factors for the spread of hiv
infection //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 49-55.
26.
Rotanov A. et al. Suicide and epidemiology and risk factors in oncological diseases
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 398-403.
27.
Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with
suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 273-277.
28.
Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and
affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 361-366.
